Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01325311 · ClinicalTrials.gov registry record · Phase 2
Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer
A Phase 2 study of Prostate Adenocarcinoma and Stage I Prostate Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 11
- Study locations
NCT01325311 is a Phase 2 study of Prostate Adenocarcinoma and Stage I Prostate Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 15 participants, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (93% lower). The trial reports 11 study locations across 9 states.
The verdict
NCT01325311, a Phase 2 study of Prostate Adenocarcinoma and Stage I Prostate Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 11
- Study locations
Study Summary
This randomized phase II trial studies cholecalciferol and genistein compared to placebo in treating patients with early stage prostate cancer. Cholecalciferol and genistein may slow the growth of cancer cells and may be an effective treatment for prostate cancer.
Conditions Studied
Interventions
- OTHER Placebo
- OTHER Laboratory Biomarker Analysis
- OTHER Pharmacological Study
- DRUG Cholecalciferol
- DRUG Genistein
Study Locations (11)
Maryland
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital - Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center - Baltimore
Minnesota
- Minneapolis Veterans Medical Center - Minneapolis
- University of Minnesota Medical Center-Fairview - Minneapolis
Alabama
- University of Alabama at Birmingham Cancer Center - Birmingham
Massachusetts
- Lahey Hospital and Medical Center - Burlington
New York
- University of Rochester - Rochester
Oklahoma
- University of Oklahoma Health Sciences Center - Oklahoma City
South Carolina
- Carolina Urologic Research Center - Myrtle Beach
Texas
- Urology San Antonio Research PA - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2011-12 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01325311
The ClinicalTrials.gov registry entry for NCT01325311 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (93% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Prostate Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT01325311 reports 11 study locations spanning 9 distinct geographic areas - top geographies include Maryland, Minnesota, Alabama.
Frequently Asked Questions
What is clinical trial NCT01325311 about?
NCT01325311 is a clinical study titled "Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer". This randomized phase II trial studies cholecalciferol and genistein compared to placebo in treating patients with early stage prostate cancer. Cholecalciferol and genistein may slow the growth of cancer cells and may be an effective treatment for prostate cancer.
What is the current status of trial NCT01325311?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2011-12. Estimated completion is 2014-07.
What conditions does trial NCT01325311 study?
This clinical trial studies the following conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIB Prostate Cancer, Stage IIA Prostate Cancer.
What interventions are being tested in trial NCT01325311?
The interventions under investigation include: Placebo (OTHER), Laboratory Biomarker Analysis (OTHER), Pharmacological Study (OTHER), Cholecalciferol (DRUG), Genistein (DRUG).
Who is sponsoring clinical trial NCT01325311?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01325311 being conducted?
This trial has 11 study locations across Alabama, Maryland, Massachusetts, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
RECRUITING · Phase 2
-
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
RECRUITING · Phase 2
-
Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)
RECRUITING · Phase 2
-
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
RECRUITING · Phase 2
-
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
RECRUITING · Phase 2
-
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.